- Home
- ETV vs CNTA Comparison
ETV vs CNTA Comparison
Compare ETV & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- CNTA
- Stock Information
- Founded
- ETV 2005
- CNTA 2020
- Country
- ETV United States
- CNTA United Kingdom
- Employees
- ETV N/A
- CNTA N/A
- Industry
- ETV Investment Managers
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- ETV Finance
- CNTA Health Care
- Exchange
- ETV Nasdaq
- CNTA Nasdaq
- Market Cap
- ETV 1.6B
- CNTA 1.6B
- IPO Year
- ETV N/A
- CNTA 2021
- Fundamental
- Price
- ETV $13.82
- CNTA $13.74
- Analyst Decision
- ETV
- CNTA Strong Buy
- Analyst Count
- ETV 0
- CNTA 10
- Target Price
- ETV N/A
- CNTA $28.78
- AVG Volume (30 Days)
- ETV 252.5K
- CNTA 1.2M
- Earning Date
- ETV 01-01-0001
- CNTA 08-12-2025
- Dividend Yield
- ETV 8.75%
- CNTA N/A
- EPS Growth
- ETV N/A
- CNTA N/A
- EPS
- ETV N/A
- CNTA N/A
- Revenue
- ETV N/A
- CNTA $15,000,000.00
- Revenue This Year
- ETV N/A
- CNTA N/A
- Revenue Next Year
- ETV N/A
- CNTA N/A
- P/E Ratio
- ETV N/A
- CNTA N/A
- Revenue Growth
- ETV N/A
- CNTA 118.88
- 52 Week Low
- ETV $11.05
- CNTA $8.46
- 52 Week High
- ETV $13.50
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- ETV 63.89
- CNTA 55.44
- Support Level
- ETV $13.69
- CNTA $12.74
- Resistance Level
- ETV $13.88
- CNTA $13.52
- Average True Range (ATR)
- ETV 0.11
- CNTA 0.66
- MACD
- ETV 0.02
- CNTA 0.08
- Stochastic Oscillator
- ETV 84.91
- CNTA 63.83
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.